A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer

被引：5

作者：

Liu, Ke-Jun ^{[1
,2
]}

Wu, Hai-Ying ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China

[2] Dongguan Peoples Hosp, Dept Med Oncol, Dongguan, Peoples R China

来源：

ONCOTARGET | 2015年 / 6卷 / 26期

关键词：

non-small-cell lung cancer (NSCLC); bevacizumab; platinum-based chemotherapy; PHASE-III TRIAL; ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; PLUS CARBOPLATIN; 2ND-LINE THERAPY; RANDOMIZED-TRIAL; 1ST-LINE THERAPY; GEMCITABINE; COMBINATION; ERLOTINIB;

D O I：

10.18632/oncotarget.4262

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with non-small-cell lung cancer (NSCLC) often have an advanced disease when firstly diagnosed. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor receptor (VEGFR). In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. Results showed that the objective response rate(ORR) of this novel regimen is 43%, median progression-free survival (PFS) was 5.2 months (95% CI, 3.7 to 6.7 months) and median overall survival (OS) was 11.4 months (95% CI, 8.8 to 13.9 months). Adverse events were generally mild, ranging from grade 1 to grade 3. In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. Randomized clinical trials are needed to further investigate the efficacy of this regimen.

引用

页码：22750 / 22757

页数：8

共 40 条

[21] Bevacizumab in combination with anticancer drugs for previously treated advanced non-small cell lung cancer [J].

Liu, Ke-jun ;

Ding, Ling-yu ;

Wu, Hai-ying .

TUMOR BIOLOGY, 2015, 36 (03) :1323-1327

[22] A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers [J].

Liu, Ke-Jun ;

Guan, Zhong-Zhen ;

Liang, Ying ;

Yang, Xu-Qing ;

Peng, Jin ;

Huang, He ;

Shao, Qing-Xiang ;

Wang, Meng-Zhao ;

Zhu, Yun-Zhong ;

Wu, Chang-Ping ;

Wang, Shao-Bin ;

Xiong, Jian-Ping ;

Bai, Yu-Xian ;

Yu, Shi-Ying ;

Zhang, Yang ;

Hu, Xiao-Hua ;

Feng, Ji-Feng ;

Wu, Shi-Xiu ;

Jiao, Shun-Chang ;

Zhou, Cai-Cun ;

Wang, Jie ;

Wu, Hai-Ying .

ARCHIVES OF MEDICAL SCIENCE, 2014, 10 (04) :717-724

[23] An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer [J].

Nuijten, Mark J. C. ;

Aultman, Rick ;

de Castro Carpeno, Javier ;

Vergnenegre, Alain ;

Chouaid, Christos ;

Walzer, Stefan ;

Siebert, Uwe .

CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (11) :2193-2201

[24]

Ogasawara Takashi, 2011, Gan To Kagaku Ryoho, V38, P1813

[25] Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study [J].

Paz-Ares, Luis ;

Mezger, Joerg ;

Ciuleanu, Tudor E. ;

Fischer, Juergen R. ;

von Pawel, Joachim ;

Provencio, Mariano ;

Kazarnowicz, Andrzej ;

Losonczy, Gyoergy ;

de Castro, Gilberto, Jr. ;

Szczesna, Aleksandra ;

Crino, Lucio ;

Reck, Martin ;

Ramlau, Rodryg ;

Ulsperger, Ernst ;

Schumann, Christian ;

Miziara, Jose Elias A. ;

Lessa, Alvaro E. ;

Dediu, Mircea ;

Balint, Beatrix ;

Depenbrock, Henrik ;

Soldatenkova, Victoria ;

Kurek, Raffael ;

Hirsch, Fred R. ;

Thatcher, Nick ;

Socinski, Mark A. .

LANCET ONCOLOGY, 2015, 16 (03) :328-337

[26] Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer [J].

Pérez-Soler, R ;

Chachoua, A ;

Hammond, LA ;

Rowinsky, EK ;

Huberman, M ;

Karp, D ;

Rigas, J ;

Clark, GM ;

Santabàrbara, P ;

Bonomi, P .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3238-3247

[27] Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL [J].

Reck, Martin ;

von Pawel, Joachim ;

Zatloukal, Petr ;

Ramlau, Rodryg ;

Gorbounova, Vera ;

Hirsh, Vera ;

Leighl, Natasha ;

Mezger, Joerg ;

Archer, Venice ;

Moore, Nicola ;

Manegold, Christian .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) :1227-1234

[28] Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [J].

Sandler, Alan ;

Gray, Robert ;

Perry, Michael C. ;

Brahmer, Julie ;

Schiller, Joan H. ;

Dowlati, Afshin ;

Lilenbaum, Rogerio ;

Johnson, David H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) :2542-2550

[29] Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer: A risk-benefit analysis of a large phase III study [J].

Scagliotti, Giorgio V. ;

Park, Keunchil ;

Patil, Shekar ;

Rolski, Janusz ;

Goksel, Tuncay ;

Martins, Renato ;

Gans, Steven J. M. ;

Visseren-Grul, Carla ;

Peterson, Patrick .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (13) :2298-2303

[30] Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer [J].

Scagliotti, Giorgio Vittorio ;

Parikh, Purvish ;

von Pawel, Joachim ;

Biesma, Bonne ;

Vansteenkiste, Johan ;

Manegold, Christian ;

Serwatowski, Piotr ;

Gatzemeier, Ulrich ;

Digumarti, Raghunadharao ;

Zukin, Mauro ;

Lee, Jin S. ;

Mellemgaard, Anders ;

Park, Keunchil ;

Patil, Shehkar ;

Rolski, Janusz ;

Goksel, Tuncay ;

de Marinis, Filippo ;

Simms, Lorinda ;

Sugarman, Katherine P. ;

Gandara, David .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3543-3551

← 1 2 3 4 →